Llwytho...

Initial Experience With Tafamidis Treatment for Transthyretin Amyloid Cardiomyopathy

Background: Transthyretin amyloid cardiomyopathy is a progressive disease with a poor prognosis. There had been no specific treatment for transthyretin amyloid cardiomyopathy until tafamidis received expanded approval in March 2019 in Japan. However, the clinical efficacy of tafamidis remains unknow...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Circ Rep
Prif Awduron: Nakamura, Makiko, Imamura, Teruhiko, Hori, Masakazu, Ushijima, Ryuichi, Joho, Shuji, Kinugawa, Koichiro
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: The Japanese Circulation Society 2020
Pynciau:
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC7819654/
https://ncbi.nlm.nih.gov/pubmed/33693263
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1253/circrep.CR-20-0062
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!